Peter A. Thompson
CIK 1357522 · Interim Chief Exec Officer · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.29B
Companies
15
Total Filings
122
Lifetime Open-Market Net
$80.10M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SION | Director | 2,671,721 | $35.92 | $95.97M | -$36.65M | 10 | 2026-05-29 |
| CRVS | Director | 8,684,091 | $11.93 | $103.60M | $10.58M | 29 | 2026-01-30 |
| SPRY | Director | 269,323 | $9.76 | $2.63M | -$9.49M | 6 | 2025-06-27 |
| EWTX | Director | 443,792 | $34.83 | $15.46M | $26.74M | 9 | 2025-06-18 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 0 | $64.97 | $0 | -$25.72M | 14 | 2024-05-20 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 327,852 | $4.91 | $1.61M | $30.00M | 3 | 2022-06-21 |
| JANX | Director | 231,098 | $13.56 | $3.13M | $1.41M | 6 | 2022-06-16 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 952,377 | $5.87 | $5.59M | $25.00M | 4 | 2022-06-13 |
| PMVP | Director | 114,039 | $1.11 | $126.6K | $17.10M | 2 | 2021-06-09 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 12,940,111 | — | — | $15.00M | 2 | 2020-06-19 |
| Synthorx, Inc. (THOR) Delisted | Director | 0 | — | — | $15.00M | 4 | 2020-01-24 |
| ASND | Director | 4,902,910 | $218.06 | $1.07B | $8.09M | 8 | 2018-06-06 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,989,949 | — | — | $2.98M | 1 | 2015-07-21 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 2 | 2012-05-10 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | President and CEO | 386,419 | — | — | $50.3K | 5 | 2009-08-28 |
Recent Filings · Page 3 of 13
122 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-12 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2024-05-20 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Mixed | −2,680,496 | $0 | EDGAR |
| 2024-05-08 | CRVS | Buy (P) | — | $0 | EDGAR |
| 2024-01-25 | EWTX | Buy (P) | +454,545 | $5.00M | EDGAR |
| 2024-01-16 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Exer (X) | +145,251 | $1.85M | EDGAR |
| 2024-01-04 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-29 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Sell (S) | −1,546,347 | -$28.67M | EDGAR |
| 2023-12-08 | CRVS | Grant (A) | — | $0 | EDGAR |
| 2023-08-31 | SPRY | Buy (P) | +500,000 | $3.10M | EDGAR |
| 2023-06-28 | SPRY | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.